Financial Performance - The company's operating revenue for Q3 2021 was ¥305,873,692.79, representing a year-on-year increase of 31.13%[7] - The net profit attributable to shareholders for Q3 2021 was ¥37,101,697.79, a decrease of 13.41% compared to the same period last year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥36,549,591.68, down 7.16% year-on-year[7] - Basic earnings per share for Q3 2021 were ¥0.069, a decrease of 12.66% compared to the previous year[9] - Net profit for the third quarter of 2021 was ¥119,564,877.53, a decrease of 18.8% from ¥147,207,024.52 in the same quarter of 2020[30] - Earnings per share for the first three quarters of 2021 were ¥0.223, down from ¥0.274 in the same period of 2020[32] - The company reported a total comprehensive income of ¥119,564,877.53 for the third quarter of 2021, compared to ¥147,207,024.52 in the same quarter of 2020[32] Cash Flow and Assets - The cash flow from operating activities for the year-to-date period decreased by 72.55%, totaling ¥55,813,707.52[7] - The cash inflow from operating activities for the first three quarters of 2021 was ¥894,946,244.82, down from ¥1,035,655,811.14 in the same period of 2020[32] - The net cash flow from operating activities was 55,813,707.52, a decrease of 72.5% compared to 203,304,422.91 in the previous year[34] - The total cash and cash equivalents at the end of the period amounted to 637,850,668.12, a decrease from 442,194,426.09 year-over-year[34] - The company's current assets totaled CNY 1,651,265,704.15, down from CNY 1,865,074,961.71 in December 2020, indicating a decline of approximately 11.4%[22] - Cash and cash equivalents were reported at CNY 658,679,556.89, compared to CNY 715,897,162.30 at the end of 2020, reflecting a decrease of about 8.0%[22] Liabilities and Equity - The total liabilities as of September 30, 2021, were CNY 332,879,220.73, down from CNY 447,827,884.09 at the end of 2020, indicating a reduction of approximately 25.6%[25] - The total liabilities as of the reporting date amounted to ¥369,416,315.94, a decrease from ¥480,245,660.39 in the previous year[29] - The company’s total non-current liabilities were reported at ¥36,537,095.21, an increase from ¥32,417,776.30 in the previous year[29] - Total liabilities amounted to 480,245,660.39, a decrease of 2,989,567.49 compared to the previous period[42] - The total equity attributable to shareholders of the parent company was ¥2,333,279,231.12, an increase from ¥2,282,816,377.57 year-over-year[29] - Total equity reached 2,379,512,640.68, reflecting a decrease of 185,057.29 from the last reporting period[42] Sales and Market Changes - The company reported a significant increase in large equipment sales, contributing to the rise in operating revenue[14] - The company experienced a change in product sales structure, with a decrease in conventional product sales and an increase in large equipment sales[14] Strategic Initiatives - The company completed a capital increase for its affiliated partnership during the reporting period, enhancing its investment capabilities[19] - The company submitted an application for a non-public offering of A-shares to the China Securities Regulatory Commission during the reporting period[19] - The company is focusing on market expansion and new product development as part of its strategic initiatives[19] Research and Development - Research and development expenses for the first three quarters of 2021 totaled ¥72,667,452.55, compared to ¥63,626,302.50 in 2020, indicating a year-over-year increase of 14.8%[30]
万东医疗(600055) - 2021 Q3 - 季度财报